Chinese drug clinical trial report in August 2019

The key information of this report is that there are 92 clinical trials of be chemical drugs registered this month, of which 47 are clinical trials of consistency evaluation; the hottest registered variety of this month is yizhejiebupian; the most concerned bidding unit of this month is Jiangsu Hengrui Pharmaceutical Co., Ltd; Data source of this report: Pharmaceutical intelligence data enterprise version, China clinical trial database, CDE drug clinical trial registration and information publicity platform (Note: PDF version of China drug clinical trial report in July and August is attached at the end of this paper) I overview of drug clinical trial registration In August 2019, 209 drug clinical trials were publicly registered in CDE (down 14.7% month on month), including 168 chemical drugs (92 chemical be clinical trials, 76 chemical clinical applications), 35 biological products and 6 traditional Chinese medicine / natural drugs 2、 In August 2019, among the drug clinical trial varieties publicized by CDE, yizheimai tablet ranked first in four registration trials, among which the two registered varieties of amoxicillin capsule and non bustat tablet in top 5 were all clinical trials for consistency evaluation, as shown in the figure below Note: this chart only lists the first five drug clinical registration varieties of this month, and there will be the same number of registration varieties not listed here later For more variety details, please go to "drug intelligence data enterprise version" of "China clinical trial database" 3、 Consistency evaluation clinical trial In August 2019, 47 out of 209 clinical trial registrations (14.7% MoM) publicized by CDE (9.3% MoM increase) were clinical trial registrations of conformity assessment Although the total number of clinical trial registrations of drugs decreased in August, the clinical trials of conformity assessment were still increasing, which can be seen from the high attention of all bidding units to conformity assessment See the table below for details Note: this table only lists 47 be tests for consistency evaluation There are 45 be tests for deemed consistency evaluation in this month that can be queried in "enterprise version of pharmaceutical intelligence data - Chinese clinical trial database" 4、 Drug clinical trial status According to the CDE announcement, by the end of August 2019, there are 9003 drug clinical trials registered, and 4013 drug clinical trials are completed here (126 drug clinical trials completed in August), 826 of which are consistency evaluation clinical trials (27 clinical trials of consistency evaluation completed in August); 4349 drug clinical trials are in the process of trial (including not yet recruited) Among them, 394 were consistency evaluation clinical trials, 247 drug clinical trial applicants applied for active suspension trials (8 new active suspension trials were added in August), of which 18 were consistency evaluation clinical trials (see the figure below for details) v clinical trial applicants concerned According to professional intelligence analysis and statistics, in August 2019, Jiangsu Hengrui Pharmaceutical Co., Ltd (ranked second in July) was the most concerned clinical trial sponsor However, in July 2019, Zhengda Tianqing Pharmaceutical Group Co., Ltd., which occupied the top of the list, dropped to the fourth place in August The sponsor of top 10 is listed here, as shown in the figure below Note: this chart only lists the first 10 interested bidding units of this month, and there will be an equal number of bidding units not listed here For more details, please consult in the following ways How to get more details of the report: 1 Pharmaceutical intelligence data Enterprise Edition ﹣ China clinical trial database https://vip.yaozh.com/linchuangshiyan 2 Pharmaceutical intelligence consultation: https://zx.yaozh.com/3 Call service hot spot: 400-678-0778 This is the original article of the professional analysis team of the pharmaceutical intelligence clinical trial database Please indicate [Author: Pharmaceutical intelligence data Enterprise Edition, source: Pharmaceutical intelligence data Enterprise Edition, China clinical trial database] for reprint To see more drug reports, please click "read the original" to enter the pharmaceutical intelligence consultation ~ Appendix 1: July 2019 pharmaceutical clinical trial report PDF Appendix 2: August 2019 drug clinical trial report.pdf statement: this view only represents the author, not the position of drug intelligence network, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.